Kevin D. Freeman‐Cook

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller et al. · Cancer Cell · 2021 · 172 citations

Tumor Biology, Oncology, Cdk2/4/6 Inhibitor +10

Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A

Casey L. Quinlan, Stephen E. Kaiser, Ben Bolaños et al. · Nature Chemical Biology · 2017 · 128 citations

Biosynthesis, Biochemistry, Natural Sciences +6

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

Kevin D. Freeman‐Cook, Robert L. Hoffman, Douglas C. Behenna et al. · Journal of Medicinal Chemistry · 2021 · 112 citations · Full text

Design of Selective, ATP-Competitive Inhibitors of Akt

Kevin D. Freeman‐Cook, Christopher Autry, Gary Borzillo et al. · Journal of Medicinal Chemistry · 2010 · 75 citations · Full text

Pharmaceutical Science, Bioorganic Chemistry, Pharmacotherapy +16

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates et al. · MedChemComm · 2011 · 68 citations